Literature DB >> 25051386

Characteristics of surgical patients receiving inappropriate empiric antimicrobial therapy.

Stephen W Davies1, Jimmy T Efird, Christopher A Guidry, Tjasa Hranjec, Rosemarie Metzger, Brian R Swenson, Robert G Sawyer.   

Abstract

BACKGROUND: Inappropriate antibiotics have been observed to result in an increased duration of antibiotic treatment and hospital length of stay, development of multidrug-resistant organisms, and mortality rate compared with appropriate antibiotic treatment. Few studies have evaluated independent risk factors associated with inappropriateness. The purpose of this study was to identify independent predictors of inappropriate, empiric antimicrobial therapy for the treatment of severe sepsis.
METHODS: This was a retrospective analysis of a prospectively maintained database of all surgical/trauma patients admitted to a tertiary care center from 1996 to 2007 and treated for sepsis. "Appropriate" empiric antibiotic treatment was determined by sensitivity testing. Demographics and comorbidities, infection sites, infection organisms, and outcomes between strata were compared. Differences in outcome were estimated using relative risk and 95% confidence intervals for correlated data.
RESULTS: A total of 2,855 patients (7,158 infections) were identified. Independent predictors of inappropriate, empiric antimicrobial therapy for the treatment of severe sepsis included site of infection and organism type. Severity of illness, age, medical conditions, and community versus health care-associated infections were not associated with inappropriate therapy. Although inappropriate empiric therapy was associated with a longer length of stay and duration of antimicrobial use, it did not result in higher mortality.
CONCLUSION: Our study observed that inappropriate empiric antibiotic selection is related to site of infection and pathogen. Other clinical variables do not appear to predict inappropriateness of antibiotic treatment. Efforts should be focused on early broad-spectrum therapy and more rapid microbiologic methods. LEVEL OF EVIDENCE: Therapeutic/care management study, level II.

Entities:  

Mesh:

Year:  2014        PMID: 25051386      PMCID: PMC4699284          DOI: 10.1097/TA.0000000000000309

Source DB:  PubMed          Journal:  J Trauma Acute Care Surg        ISSN: 2163-0755            Impact factor:   3.313


  38 in total

Review 1.  [Risk of superinfection related to antibiotic use. Are all antibiotics the same?].

Authors:  C Alvarez; J M Ramos; R San Juan; C Lumbreras; J M Aguado
Journal:  Rev Esp Quimioter       Date:  2005-03       Impact factor: 1.553

2.  Inappropriate initial treatment of secondary intra-abdominal infections leads to increased risk of clinical failure and costs.

Authors:  Miriam C J M Sturkenboom; Wim G Goettsch; Gino Picelli; Bas in 't Veld; Don D Yin; Romy B de Jong; Peter M N Y H Go; Ron M C Herings
Journal:  Br J Clin Pharmacol       Date:  2005-10       Impact factor: 4.335

3.  Conference summary: ventilator-associated pneumonia.

Authors:  Jean Chastre
Journal:  Respir Care       Date:  2005-07       Impact factor: 2.258

4.  Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients.

Authors:  Eric W Mueller; Scott D Hanes; Martin A Croce; G Christopher Wood; Bradley A Boucher; Timothy C Fabian
Journal:  J Trauma       Date:  2005-01

5.  Nosocomial bacteremia in critically ill patients: a multicenter study evaluating epidemiology and prognosis. Spanish Collaborative Group for Infections in Intensive Care Units of Sociedad Espanola de Medicina Intensiva y Unidades Coronarias (SEMIUC).

Authors:  J Vallés; C León; F Alvarez-Lerma
Journal:  Clin Infect Dis       Date:  1997-03       Impact factor: 9.079

6.  Impact of BAL data on the therapy and outcome of ventilator-associated pneumonia.

Authors:  C M Luna; P Vujacich; M S Niederman; C Vay; C Gherardi; J Matera; E C Jolly
Journal:  Chest       Date:  1997-03       Impact factor: 9.410

7.  Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients.

Authors:  M H Kollef; G Sherman; S Ward; V J Fraser
Journal:  Chest       Date:  1999-02       Impact factor: 9.410

8.  Nosocomial bacteremia in a medical-surgical intensive care unit: epidemiologic characteristics and factors influencing mortality in 111 episodes.

Authors:  J Rello; M Ricart; B Mirelis; E Quintana; M Gurgui; A Net; G Prats
Journal:  Intensive Care Med       Date:  1994       Impact factor: 17.440

9.  The benefit of appropriate empirical antibiotic treatment in patients with bloodstream infection.

Authors:  L Leibovici; I Shraga; M Drucker; H Konigsberger; Z Samra; S D Pitlik
Journal:  J Intern Med       Date:  1998-11       Impact factor: 8.989

10.  The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee.

Authors:  J L Vincent; D J Bihari; P M Suter; H A Bruining; J White; M H Nicolas-Chanoin; M Wolff; R C Spencer; M Hemmer
Journal:  JAMA       Date:  1995 Aug 23-30       Impact factor: 56.272

View more
  3 in total

1.  Interleukin-6 Kinetics can be Useful for Early Treatment Monitoring of Severe Bacterial Sepsis and Septic Shock.

Authors:  Thomas Klag; Giulio Cantara; Udo Sechtem; Anastasios Athanasiadis
Journal:  Infect Dis Rep       Date:  2016-03-21

2.  Association of Peripheral Arterial Occlusive Disease and Deep Venous Thrombosis with Risk of Consequent Sepsis Event: A Retrospective Population-Based Cohort Study.

Authors:  Bo-Yuan Wang; Ying-Hsiang Chou; Chi-Tzu Chung; Shun-Fa Yang; Shu-Ling Tzeng; Yu-Hsun Wang; Ming-Chih Chou; Chao-Bin Yeh; Chi-Ho Chan
Journal:  Int J Environ Res Public Health       Date:  2022-05-31       Impact factor: 4.614

3.  Antibiotic use among older adults on an acute care general surgery service.

Authors:  André S Pollmann; Jon G Bailey; Philip J B Davis; Paul M Johnson
Journal:  Can J Surg       Date:  2017-12       Impact factor: 2.089

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.